<- Go Home
Poolbeg Pharma PLC
Poolbeg Pharma PLC, a clinical-stage biopharmaceutical company, engages in developing immunotherapy for cancer in the United Kingdom. The company develops POLB 001, which is completed phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome; and phase 2 for the treatment of influenza. It also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; and AI program, a novel drug discovery therapies for the treatment of influenza and respiratory syncytial viruses. Poolbeg Pharma plc was incorporated in 2021 and is based in London, United Kingdom.
Market Cap
GBP 43.4M
Volume
1.7M
Cash and Equivalents
GBP 7.7M
EBITDA
-GBP 6.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
GBP 0.09
52 Week Low
GBP 0.03
Dividend
N/A
Price / Book Value
4.99
Price / Earnings
-6.51
Price / Tangible Book Value
6.19
Enterprise Value
GBP 35.7M
Enterprise Value / EBITDA
-5.68
Operating Income
-GBP 6.3M
Return on Equity
63.72%
Return on Assets
-39.20
Cash and Short Term Investments
GBP 7.7M
Debt
N/A
Equity
GBP 8.6M
Revenue
N/A
Unlevered FCF
-GBP 2.9M
Sector
Pharmaceuticals
Category
N/A